Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.

Name: Αlpha¹ Rigor Record — Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
Item: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
Rating: 96
Author: Αlpha¹

Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, Lincoff AM, McGuire DK, Miller D, Nauck MA, Nishiyama H, Nissen SE, Sattar N, Weerakkody G, Wiese RJ, Zinman B, Zoungas S, Basile J, Davies MJ, Giorgino F, Kellerer M, Ji L, Varkonyi T, Menon V, Broder JC, Herschtal A, D'Alessio D, SURPASS-CVOT Investigators

Paper source

Read full text

Embed this Rigor badge

Αlpha¹ Rigor Review — 4.25★ (Strong), 0 critical, 2 high issues for “Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

4.25 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 22 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Problems surfaced2 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported randomized controlled trial with strong methodological rigor across most dimensions. The primary weakness is the vague data availability statement, which does not specify the access mechanism or repository.

Both reviewers agreed on study type (interventional). All eight dimensions were applicable; no dimensions were excluded as not applicable. The reviewers' assessments were highly concordant, with minor divergence on the regulatory compliance sub-criterion within ethical approvals, which did not affect the overall status.

7 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites multiple prior trials showing GLP-1 receptor agonists reduce cardiovascular events and that tirzepatide improves metabolic risk factors, but notes the lack of a dedicated cardiovascular outcomes trial. The rationale for using dulaglutide as an active comparator is explicitly stated, and the noninferiority margin is justified. Limitations of prior work (small, short-duration pooled analyses) are acknowledged in the Discussion.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a clear scientific premise by citing prior trials of GLP-1 receptor agonists and tirzepatide, and provides a logical rationale for the noninferiority design.

Evidence

direct quote[Introduction, paragraph 1]

“Clinical trials have shown that glucagon-like peptide-1 (GLP-1) receptor agonists reduce the incidence of major adverse cardiovascular events among patients with high cardiovascular risk and type 2 diabetes, 2-7 chronic kidney disease, 8,9 or obesity. 10”